熱門資訊> 正文

Apellis Pharmaceuticals报告第四季度业绩

2026-02-24 20:09

Apellis Pharmaceuticals press release (APLS): Q4 net loss of $58.9 million, compared to a net loss of $36.4 million for the same period in 2024.
Revenue of $199.9M (-5.9% Y/Y) beats by $0.46M.
Cash and cash equivalents of $466 million as of December 31, 2025; projected revenues, cash, and cash equivalents expected to be sufficient to fund operations to profitability

More on Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc. (APLS) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
Apellis Pharmaceuticals, Inc. (APLS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Apellis Pharmaceuticals: A Good Product That Just Misses The Mark
Apellis Pharmaceuticals Q4 2025 Earnings Preview
TTM Technologies, Dutch Bros to join S&P 400 Index; Amneal, Apellis to be part of S&P SmallCap 600

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。